CC vs CGAU
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Chemours Company exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and an alarming Debt/Equity ratio of 17.51. While the stock has seen a massive 1-year price surge of 119.6%, this momentum is decoupled from fundamentals, as evidenced by a negative ROE of -93.80% and shrinking revenue. The dividend is unsustainable with a payout ratio of 555.56%, and the current price of $26.61 already exceeds the analyst target price of $21.67. Overall, the company appears to be in a high-risk state with significant solvency concerns.
CGAU presents a stark contrast between exceptional valuation and deteriorating fundamental trends. While the stock is significantly undervalued relative to its Graham Number ($25.67) and Intrinsic Value ($19.88), the Piotroski F-Score of 3/9 indicates weak financial health and negative operational trends. Despite a near-zero debt profile and high profitability, the bearish technical trend (10/100) and an analyst target price ($17.75) below the current market price suggest immediate headwinds.
Compare Another Pair
CC vs CGAU: Head-to-Head Comparison
This page compares The Chemours Company (CC) and Centerra Gold Inc. (CGAU) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.